AbbVie Invests $100B in US R&D to Combat Drug Pricing with Trump Alliance
- AbbVie on Tuesday announced a voluntary agreement with the Trump administration aimed at expanding access to medicines adn lowering costs for US patients while preserving domestic pharmaceutical innovation.1...
- As part of the deal,AbbVie is expanding its direct-to-patient offerings through the TrumpRx program,making widely used medications such as brimonidine tartrate (Alphagan),brimonidine/timolol (Combigan),adalimumab (humira),and levothyroxine sodium (Synthroid) more...
- The AbbVie agreement comes amid a broader push by the Trump administration to secure voluntary drug pricing concessions from major pharmaceutical manufacturers.3 To date,the administration has reached pricing...
AbbVie on Tuesday announced a voluntary agreement with the Trump administration aimed at expanding access to medicines adn lowering costs for US patients while preserving domestic pharmaceutical innovation.1 Under the agreement, the company will offer lower prices for its drugs in Medicaid and commit $100 billion over the next decade to US-based research and development and capital investments, including manufacturing.
As part of the deal,AbbVie is expanding its direct-to-patient offerings through the TrumpRx program,making widely used medications such as brimonidine tartrate (Alphagan),brimonidine/timolol (Combigan),adalimumab (humira),and levothyroxine sodium (Synthroid) more accessible to
With approximately 29,000 U.S.-based employees and products treating 16 million Americans annually, we understand the complexity and access challenges in our healthcare system. AbbVie is following President Trump’s call to action by reaching this agreement, allowing us to collectively move beyond policies that harm American innovation. Thank you to President Trump and his team for their leadership to help deliver cost savings and supporting our efforts to deliver innovative treatments for American patients.
Trump’s Push for Most-Favored-Nation Pricing Deals
Table of Contents
The AbbVie agreement comes amid a broader push by the Trump administration to secure voluntary drug pricing concessions from major pharmaceutical manufacturers.3 To date,the administration has reached pricing agreements with most of the companies it contacted. Johnson & Johnson joined the list recently, announcing its agreement on January 9.4 With participation from Johnson & Johnson and now AbbVie,the Trump administration is waiting on one final response from Regeneron.
Central to these deals is a requirement that manufacturers offer most of their drugs to Medicaid at prices comparable to those charged internationally, alongside participation in a new federal initiative, TrumpRx.gov, designed to steer patients toward direct-from-manufacturer purchasing options.3
The agreements reflect a scaled-back version of Trump’s revived most-favored-nation agenda, relying on negotiated commitments rather than mandatory regulation. In exchange, par
The agreement between AbbVie and the Trump administration aims to improve access to and affordability of AbbVie’s medications for Americans. As part of the deal, AbbVie committed to limit price increases on its drugs and to invest $100 billion in the United States. The administration, in turn, agreed to grant AbbVie a tariff reprieve. This model will lead to broader, enforceable price reforms across the pharmaceutical market.
References
- AbbVie and Trump administration reach agreement to improve access and affordability for Americans. News release. AbbVie. January 12, 2026. Accessed January 13, 2026. https://news.abbvie.com/2026-01-12-AbbVie-and-Trump-Administration-Reach-Agreement-to-Improve-Access-and-Affordability-for-Americans
- Kansteinor F. AbbVie inks latest White House drug pricing deal, scoring tariff reprieve as it makes $100B US investment pledge. Fierce Pharma. January 13,2026. Accessed January 13, 2026.
Trump Administration’s Drug Pricing Effort and pharmaceutical Company Agreements
In 2018, the Trump administration initiated an effort to lower prescription drug prices, culminating in an agreement with several pharmaceutical companies to voluntarily roll back price increases.
The initiative, announced in February 2020, involved commitments from 15 of the 17 largest pharmaceutical companies to refrain from raising drug prices for the remainder of the year. This pledge was made shortly before the 2020 presidential election. The agreement was not legally binding and relied on voluntary compliance.
According to a press release from the Department of Health and Human Services (HHS), the companies involved included AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi, and Viatris (then Mylan).
Verification of Company Participation (as of january 13,2026)
As of January 13,2026,the status of these commitments and their long-term impact remains a subject of analysis. While the initial agreement covered price freezes through the end of 2020, subsequent price increases have occurred. A report by the Kaiser Family Foundation (KFF) examined drug price increases in 2021,finding that list prices for many brand-name drugs continued to rise despite the prior pledge.
The agreement’s effectiveness was limited by its voluntary nature and the lack of enforcement mechanisms. furthermore, the pledge did not cover all drugs, and companies were still able to raise prices on certain medications.
The Biden Administration’s Approach to Drug Pricing
The Biden administration has pursued a different approach to lowering drug prices, focusing on legislation and regulatory actions. The Inflation Reduction Act of 2022, signed into law in August 2022, allows Medicare to negotiate prices for certain high-cost drugs, a key policy change that was not part of the Trump administration’s strategy.
The Inflation Reduction Act represents a important shift in federal drug pricing policy,moving away from voluntary agreements towards government negotiation. The first drugs subject to negotiation under the Inflation Reduction Act are expected to have lower prices available starting in 2026. CMS proclamation details the first 10 drugs selected for negotiation.
Impact of the 2020 Agreement
The 2020 agreement had a limited, short-term impact on drug prices. While some companies did adhere to the pledge, the overall effect on affordability was minimal. the agreement primarily served as a public relations effort by the Trump administration.
A study published in Health Affairs found that the agreement did not lead to substantial or sustained reductions in drug spending.